Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 3;10(21):5159.
doi: 10.3390/jcm10215159.

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response

Florian Terrec  1 , Thomas Jouve  1   2 , Paolo Malvezzi  1 , Bénédicte Janbon  1 , Hamza Naciri Bennani  1 , Lionel Rostaing  1   2 , Johan Noble  1   2
Affiliations
Review

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response

Florian Terrec et al. J Clin Med. .

Abstract

Belatacept is a common immunosuppressive therapy used after kidney transplantation (KT) to avoid calcineurin-inhibitor (CNI) use and its related toxicities. It is unclear whether its use exposes KT recipients (KTx) to a greater risk of infection or a poorer response to vaccines. Areas covered: We reviewed PubMed and the Cochrane database. We then summarized the mechanisms and impacts of belatacept use on the risk of infection, particularly opportunistic, in two settings, i.e., de novo KTx and conversion from CNIs. We also focused on COVID-19 infection risk and response to SARS-CoV-2 vaccination in patients whose maintenance immunosuppression relies on belatacept. Expert opinion: When belatacept is used de novo, or after drug conversion the safety profile regarding the risk of infection remains good. However, there is an increased risk of opportunistic infections, mainly CMV disease and Pneumocystis pneumonia, particularly in those with a low eGFR, in older people, in those receiving steroid-based therapy, or those that have an early conversion from CNI to belatacept (i.e., <six months post-transplantation). Thus, we recommend, if possible, delaying conversion from CNI to belatacept until at least six months post-transplantation. Optimal timing seems to be eight months post-transplantation. In addition, KTx receiving belatacept respond poorly to SARS-CoV-2 vaccination.

Keywords: CD80/CD86; belatacept; cytomegalovirus; immunosuppressive regimen; kidney transplantation; opportunistic infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Starzl T.E., Fung J., Jordan M., Shapiro R., Tzakis A., McCauley J., Johnson J., Iwaki Y., Jain A., Alessiani M. Kidney transplantation under FK 506. JAMA. 1990;264:63–67. doi: 10.1001/jama.1990.03450010067032. - DOI - PMC - PubMed
    1. Myers B.D., Ross J., Newton L., Luetscher J., Perlroth M. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984;311:699–705. doi: 10.1056/NEJM198409133111103. - DOI - PubMed
    1. Rodrigo E., Fernández-Fresnedo G., Valero R., Ruiz J.C., Pinera C., Palomar R., Gonzalez-Cotorruelo J., Gomez-Alamillo C., Arias M. New-onset diabetes after kidney transplantation: Risk factors. J. Am. Soc. Nephrol. 2006;17((Suppl. 3)):S291–S295. doi: 10.1681/ASN.2006080929. - DOI - PubMed
    1. Hošková L., Málek I., Kopkan L., Kautzner J. Pathophysiological mechanisms of calcineurin inhibitorinduced nephrotoxicity and arterial hypertension. Physiol. Res. 2017;66:167–180. doi: 10.33549/physiolres.933332. - DOI - PubMed
    1. Wojciechowski D., Vincenti F. Current status of costimulatory blockade in renal transplantation. Curr. Opin. Nephrol. Hypertens. 2016;25:583–590. doi: 10.1097/MNH.0000000000000268. - DOI - PubMed